E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Documented asthma for at least 6 months before screening Subjects with a FEV1 of between 50-85% of the predicted normal value for age, height and gender after withholding short acting Beta2-agonists for at least 6 hours and long-acting Beta2-agonists for at least 24 hours.
|
|
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To assess the clinical comparability of salbutamol-HFA 134a and Ventolin Evohaler® in a cumulative dose design |
|
E.2.2 | Secondary objectives of the trial |
To evaluate the safety and tolerability of salbutamol-HFA 134a |
|
E.2.3 | Trial contains a sub-study | Information not present in EudraCT |
E.3 | Principal inclusion criteria |
At study entry: 1.Male and female asthmatic patients, aged 18 - 45 years inclusive. 2. Documented asthma for at least 6 months before screening. 3.Subjects with a FEV1 between 50% and 85% of the predicted normal value for age, height and gender. 4.Subjects who demonstrate a reversibility of > 12% in FEV1 10 minutes after a dose of 200g salbutamol from a standard salbutamol pMDI, after withholding short acting 2-agonists for at least 6 hours and long acting 2-agonists for at least 24 hours. 5.Subjects who are able to handle a pMDI correctly without the aid of air chambers. 6.Subjects who are willing to give written informed consent to participate in the study.
On study days: 1.A pre-dose baseline FEV1 within 10% of the value obtained at the Screening Visit. |
|
E.4 | Principal exclusion criteria |
1.Patients currently receiving oral corticosteroid therapy or who have received oral corticosteroid therapy in the 3 months preceding the screening. 2.Patients currently receiving therapy for an upper respiratory tract infection or who have received such a therapy in the month prior to the start of the study. 3.Patients who have been hospitalised or received emergency treatment for an exacerbation of asthma in the 3 months prior to the start of the study. 4.Patients with a known or suspected hypersensitivity to salbutamol or it’s excipients. 5.Patients who have experienced bronchospasms following the administration of HFA 134a containing products. 6.Patients who are unable to perform lung function tests. 7.Patients with any of the following concurrent conditions: •Uncontrolled diabetes mellitus •Evidence of current neoplastic disease other than basal cell carcinoma •Evidence of tuberculosis •Evidence of significant cardiovascular disease •Respiratory disorders other than asthma or rhinitis •Significant hepatic or renal insufficiency. •Evidence or history of alcohol or drug abuse. •Evidence or history of low potassium levels. 8.Patients currently receiving other investigational medication or who have received investigational medication in the 3 months prior to the screening of the study. 9.Employees of Merck Generics [UK] Ltd. or the CRO responsible for the execution of the study. 10.Women who are pregnant, lactating or likely to become pregnant during the course of the study. Women of child bearing potential will be eligible to enter the study if using adequate contraception (i.e. contraceptive pill or barrier methods). |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Since this is a cross-over trial no endpoint period is defined. The baseline periods for assessment of the change in FEV1 is defined as the values obtained before T=0.00 hr at Visit 1 and Visit 2 |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | Information not present in EudraCT |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | Yes |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | Yes |
E.8.1.7 | Other | Yes |
E.8.1.7.1 | Other trial design description |
|
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Information not present in EudraCT |
E.8.2.2 | Placebo | Information not present in EudraCT |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
|
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | Information not present in EudraCT |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 0 |
E.8.9.1 | In the Member State concerned months | 4 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 0 |
E.8.9.2 | In all countries concerned by the trial months | 4 |